ClinicalTrials.gg

Program

Bismuth

Also written as “Bismuth Potassium Citrate Capsules”.

Its studies are led by 4 companies.

Furthest: phase 1, since Aug 20, 20194 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
HK inno.N10 open or runningphase 1since Aug 20, 2019Aug 20, 2019none ahead
Jiangsu Sinorda Biomedicine10 open or runningphase 1since Sep 4, 2025Sep 4, 2025none ahead
Shandong Luoxin Pharmaceutical Group Stock10 open or runningphase 1since Jun 2, 2023Jun 2, 2023none ahead
Sihuan Pharmaceutical Holdings Group10 open or runningphase 1since May 15, 2020May 15, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 20, 2019First study: phase 1 study in HealthyNew to HK inno.NHK inno.N · NCT04066257 · 32 enrolled · Korea, Republic of
  2. May 15, 2020Sihuan Pharmaceutical Holdings Group's first study: phase 1 study in Healthy Male VolunteersNew to Sihuan Pharmaceutical Holdings GroupSihuan Pharmaceutical Holdings Group · NCT04444011 · 32 enrolled
  3. Jun 2, 2023Shandong Luoxin Pharmaceutical Group Stock's first study: phase 1 study in HealthyNew to Shandong Luoxin Pharmaceutical Group StockShandong Luoxin Pharmaceutical Group Stock · NCT05915871 · 22 enrolled · China
  4. Sep 4, 2025Jiangsu Sinorda Biomedicine's first study: phase 1 study in Healthy VolunteersNew to Jiangsu Sinorda BiomedicineJiangsu Sinorda Biomedicine · NCT07294846 · 56 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07294846Healthy Volunteers · China1CompletedJiangsu Sinorda BiomedicineDec 15, 202556
NCT05915871Healthy · China1CompletedShandong Luoxin Pharmaceutical Group StockApr 28, 202322
NCT04444011Healthy Male Volunteers1UNKNOWNSihuan Pharmaceutical Holdings GroupSep 30, 202032
NCT04066257Healthy · Korea, Republic of1CompletedHK inno.NFeb 22, 201932

How it is read

Names in the registry

  • “Bismuth”, 3 entries
  • “Bismuth Potassium Citrate Capsules”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.